Home    Products    Wegovy Lawsuit

WINDER LAW FIRM

Wegovy Lawsuit

Individuals have filed Wegovy lawsuits alleging side effects such as gastroparesis and vision loss. They also claim that the drug’s manufacturers allegedly failed to warn of these risks adequately. Individual lawsuits from across the United States have been consolidated into a Multidistrict Litigation (MDL).

Have you experienced severe side effects from Wegovy? Request a free case evaluation to discuss your legal options.

No Upfront Legal Fees

Free, Confidential Case Review

Replies Within 1 Business Day

Virtual Consultations Available

2025 Wegovy Lawsuit update

We keep track of the case so you don’t have to

Key Takeaways

  • Lawsuits allege that Wegovy is linked to severe side effects like gastroparesis and vision loss. They accuse the manufacturer, Novo Nordisk, of providing inadequate warnings.
  • Individual cases have been consolidated into multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania. There are over 1,800 active cases as of May 2025.
  • Claims focus on alleged inadequate warnings and deceptive marketing by Novo Nordisk.
  • Novo Nordisk cites the ‘learned intermediary’ doctrine, asserting that they inform doctors of risks. Doctors are then responsible for warning patients.

Recent Wegovy lawsuit updates

June 6, 2025 - Wegovy May Cause NAION

European Medicines Agency concluded that Wegovy may cause rare occurrences of NAION (non-arteritic anterior ischemic optic neuropathy), a type of sudden and usually permanent blindness.

June 2, 2025 - Wegovy May Cause Hair Loss

A study in JAAD suggested Wegovy and other semaglutide drugs may cause hair loss. Scientists also called for further research.

This Lawsuit Is Active

Introduction to the Wegovy Lawsuit

Wegovy is a brand name for the drug semaglutide. The primary purpose is to aid in weight loss for adults. Wegovy is often associated with the big-name drug Ozempic.

The FDA approved the drug for weight loss in 2021. Wegovy was developed to support weight loss in adults and has been widely prescribed for that purpose. The benefits of this drug are now in conflict with potential health risks.

Wegovy is currently being scrutinized by the legal system due to its side effects. Some users of the drug who had allegedly harmful side effects have filed lawsuits.

These lawsuits allege that Novo Nordisk, the manufacturer, failed to provide adequate warnings to users. Lawsuits say they did not clearly disclose the potential risks associated with Wegovy.

The lawsuits claim that Wegovy can lead to serious conditions. Many conditions are currently under testing and investigation. The main condition that users allege is caused by Wegovy is:

  • Gastroparesis – A condition that makes it difficult for the stomach to empty itself.

Please keep in mind that the lawsuits are currently accusations. The legal process is ongoing.

Wegovy Drug Facts

Active Ingredient
Semaglutide
Uses
Weight loss, heart problems
Manufacturer
Novo Nordisk
Dosages
0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg
Common Side Effects
Nausea, vomiting, diarrhea, abdominal pain and constipation
Boxed Warning
T-cell thyroid tumors and medullary thyroid carcinoma (MTC)

Wegovy Lawsuit Overview

The scope of the Wegovy suit contains thousands of individual lawsuits. Many individual Wegovy lawsuits have now been consolidated into a single multidistrict litigation (MDL). MDLs aim to reduce redundancy and facilitate efficient case management. 

A lawsuit set up through an MDL means central management. This will enable smoother pretrial proceedings. In recent months, the lawsuits were centralized in the Eastern District of Pennsylvania. All of this reflects the complexity and national scope of the litigation.

Central to the legal debates are two primary concerns:

  • Claims allege Novo Nordisk failed to properly warn users about serious side effects. 
  • Claims allege the company used deceptive marketing practices.

It is alleged that Novo Nordisk marketed Wegovy to the public as a safe and effective way to lose weight. Lawsuits also claim they didn’t disclose the risks involved. According to Novo Nordisk, the lawsuits are without merit, and they plan to defend themselves.

Is There a Wegovy Class Action Lawsuit?

There is no Wegovy class action lawsuit. Instead, this kind of lawsuit, which many people can join, is what’s known as a mass tort. The suit is managed under multidistrict litigation (MDL). MDLs consolidate many related cases into a single case for pretrial proceedings, but then individual lawsuits are handled separately.

Understanding Multidistrict Litigation (MDL)

An MDL combines complex lawsuits that have similar legal issues. It centralizes many of the proceedings into one court to streamline processes.

MDLs are useful when each person’s case is a bit different, as opposed to a class action. They help make sure everyone’s unique situation is considered. This makes the legal process more efficient for groups of related cases.

There are lots of benefits to an MDL in complex lawsuits. They prevent repetitive discovery and inconsistent rulings. It can also accelerate the legal process for large groups of related cases. The potential downside is the possibility of longer wait times for certain users who filed lawsuits.

Wegovy Side Effects, Risks & Symptoms

Wegovy is a medication for weight loss that works by making users feel full longer. This offers numerous benefits for weight management. Though on the contrary, it also poses potential adverse side effects, among which gastroparesis and vision loss have been reported in some users.

Gastroparesis

Gastroparesis, or delayed gastric emptying, is a very serious condition. Studies have pointed to an incidence rate of about 10 cases per 1,000 users. The symptoms are severe: nausea, vomiting, and abdominal pain. That is why it is necessary to conduct cautious monitoring.

More Reported Side Effects

Other side effects reported by users are currently under review. They have not yet been definitively linked in the ongoing Multidistrict Litigation (MDL). 

Blood Clots

While rare cases of blood clots have been reported, they are not a major focus of current Wegovy litigation or FDA warnings. Research, including the SUSTAIN and PIONEER trials, suggests an increased risk of complications. Deep vein thrombosis (DVT) has been observed in users of semaglutide. DVT is a serious condition that can become life-threatening if it travels to the lungs or heart.

Gallbladder Issues

Users have reported gallbladder-related problems. Issues like gallstones can lead to surgical intervention. Some symptoms that may be present include abdominal pain, fever, jaundice, and clay-colored stools.

Intestinal Blockage and Ileus

The US Food and Drug Administration has approved updates to the drug labels for medicines containing semaglutide following reports of cases of intestinal blockage. The updated labeling for medicines containing the drug now includes warnings about the risks of intestinal blockage, or ileus, which can cause symptoms such as severe abdominal pain and persistent vomiting.

Gastroenteritis

One of these reported side effects is gastroenteritis, an infection in the intestines. Medications that include semaglutide could lead to the development of this condition. Some of the symptoms that they need to watch out for include severe abdominal pain and diarrhea.

Bowel Obstruction

Some reports and regulatory updates have noted a possible increased risk of bowel obstruction with semaglutide use. This condition involves a blockage of the bowel and typically requires immediate medical attention.

Other common side effects provided by the manufacturer include:

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Stomach pain
  • Headache
  • Tiredness (fatigue)
  • Upset stomach
  • Dizziness
  • Feeling bloated
  • Belching
  • Gas
  • Stomach flu
  • Heartburn

Alleged side effects may significantly impact an individual’s daily life. For example, patients with gastroparesis may feel perpetual nausea and vomiting. It causes nutritional deficiency and decreases the quality of life. Severe cases may require ongoing medical attention and can significantly affect a patient’s quality of life.

Do you experience any of the symptoms above?

Let’s discuss your legal options in a free case review. Information-mark-

Key Legal Proceedings and Milestones

May 23, 2025 – Wegovy Loses To Mounjaro In Trial

BBC reported Wegovy lost to Mounjaro in a head-to-head trial for weight loss effectiveness.

May 8, 2025 – Approval Sought for Wegovy Pill

Novo Nordisk seeks FDA approval for pill version of Wegovy.

May 5, 2025 – ER Visits Attributed to Semaglutides

A study in the Annals of Internal Medicine attributed 25,000 ER visits to semaglutide drugs like Wegovy, mainly for gastrointestinal issues.

May 1, 2025 – Lawsuits Continue To Climb

The GLP-1 lawsuit count reached 1,809 cases.

April 2, 2025 – Record Earnings for Novo Nordisk

Novo Nordisk reported record earnings driven by sales of Wegovy and Ozempic.

March 14, 2025 – Link Between Wegovy and Hair Loss

A newly published study strengthens the potential link between semaglutide medications, such as Wegovy, and hair loss. According to CNBC, patients taking semaglutide were found to have a 52% higher risk of experiencing hair loss compared to those using non-semaglutide weight-loss drugs.

March 5, 2025 – Wegovy Discounted for Cash Paying Customers

Reuters reported Novo Nordisk is offering Wegovy at a discounted rate to cash-paying customers amid a crackdown on compounded versions.

March 3, 2025 – Wegovy Removed from Shortage List

The FDA removed Wegovy from the drug shortage list.

December 13, 2024 – Wegovy Label Updated

The FDA updated the Wegovy label to include severe gastrointestinal risks.

November 22, 2024 – Thyroid Cancer Concerns Raised

An Endocrine Connections study raised thyroid cancer concerns for GLP-1 drugs like Wegovy.

August 12, 2024 – Concerns Over Weight Loss Drugs and Eating Disorders

A recent report suggests GLP-1 drugs, like Wegovy, may increase the risk of developing or worsening eating disorders. These medications need close monitoring for signs of disordered eating. Note: These concerns are not currently part of the ongoing MDL.

July 7, 2024 – Vision Loss Risk Linked to Wegovy Use

A new study shows Wegovy may increase the risk of vision loss (Nonarteritic Anterior Ischemic Optic Neuropathy – NAION). Dr. Jimena Hathaway’s study followed over 16,000 people for six years. It found those taking Wegovy were four to seven times more likely to develop NAION. Similar risks were found for Ozempic and Rybelsus.

June 6, 2024 – Judge Passed Away

Judge Gene E.K. Pratter sadly passed away, briefly putting the Wegovy Lawsuit on hold. She was replaced by Judge Karen Marston, who now oversees the weight loss drug MDL.

April 2024 – Proposed Slate of Lawyers

A slate of lawyers recommended by the plaintiffs’ steering committee is selected to navigate the Wegovy litigation. They handle discovery, argue key motions, and coordinate communication among plaintiff representatives.

March 2024 – MDL Consolidation Confirmed and Judge Assigned

Judge Gene E.K. Pratter was selected by the Court to preside over the Wegovy litigation. The Judicial Panel on Multidistrict Litigation consolidated Wegovy lawsuits into one MDL in the Eastern District of Pennsylvania to streamline pretrial proceedings.

February 2024 – MDL Initial Consolidation

The U.S. Judicial Panel on Multidistrict Litigation consolidated over 55 lawsuits, centralizing semaglutide-related cases in the Eastern District of Pennsylvania. This order anticipated many more to come and aimed to streamline pretrial efficiency.

January 2024 – FDA Evaluation on Suicidal Thoughts

The FDA announced results of its investigation into suicidal ideation with semaglutide use. They found no clinical evidence linking these drugs to suicidal behavior, though a slight risk couldn’t be ruled out.

December 2023 – Judicial Progress in Failure-to-Warn Case

A federal judge in Louisiana allowed a major case against Ozempic and Wegovy to move forward on failure-to-warn claims. All other claims were dismissed.

November 2023 – Canadian Class-Action Initiation

A class-action lawsuit was initiated in Canada, claiming Novo Nordisk failed to disclose risks such as gastroparesis.

September 2023 – FDA Warning Update

The FDA updated warning labels for Ozempic and Wegovy to include intestinal blockage and ileus.

August 2023 – Early Lawsuit Filings

Jaclyn Bjorklund filed one of the earliest complaints against Ozempic and Mounjaro, citing gastroparesis.

July 2023 – Medication Shortage Report

Drug shortages affected both Ozempic and Wegovy, highlighting demand and supply issues.

August 2022 – Beginning of Legal Proceedings for Patent Infringement

Seven lawsuits were consolidated in Delaware alleging patent violations for Ozempic generics. Around the same time, allegations surfaced linking Ozempic with gallbladder problems.

Legal Scrutiny Over Semaglutide Side Effects

As stated above, Lawsuits have been raised because of semaglutide. This is an active ingredient in the drug Wegovy. The claims indicate that semaglutide caused severe problems with some people’s gastrointestinal systems.

The court will assess the link between side effects and health risks. Legal proceedings take place on whether the warnings were enough or not. Then the court will decide whether the warnings given were sufficient or not.

The Science Behind Wegovy and Legal Implications

Studies suggest semaglutide may slow the emptying of the stomach. This is significant in legal arguments regarding patient harm from having taken Wegovy.

Lawsuits are attempting to argue that the manufacturer, Novo Nordisk, was aware of the risks. Awareness of risks but failing to warn is central to this case.

Exploring the Ingredients in Wegovy

The principal active ingredient in Wegovy is semaglutide. Semaglutide is a GLP-1 receptor agonist designed to mimic a hormone naturally found in the body.

Inactive ingredients include sodium phosphate dibasic dihydrate, sodium chloride, and water.

They each have specific purposes. Sodium phosphate dibasic dihydrate acts as a buffering agent. Sodium chloride maintains tonicity. Water is the injection vehicle. Each of the elements plays a role in the stability and delivery of the medication.

The role of these other ingredients is being analyzed and investigated as well.

Attorneys and scientists analyze how each ingredient might interact with the human body. 

Thereby, they may affect the drug’s effectiveness. Or, they could add to the adverse reactions reported by consumers. That is where a more plausible connection could potentially be made. It might link Wegovy’s composition with specific health issues.

Gastroparesis Claims in Wegovy Lawsuits

Gastroparesis is an important point in Wegovy lawsuits. This is a condition where stomach emptying is delayed without physical blockage.

Symptoms of this condition include nausea, vomiting, abdominal pain, and a feeling of fullness. All impact quality of life. These symptoms are often highlighted in individual lawsuits. They show the possible adverse effects of medications like Wegovy.

Two cases in particular suggest a link between Wegovy and gastroparesis. In one case, a man with a history of type 2 diabetes began semaglutide therapy. He later developed significant gastroparesis symptoms. Stopping the medication appeared to lead to a marked improvement in symptoms. A repeat gastric emptying study showed normal results.”

This is one of many claims that have led to the ongoing investigation of a potential link to gastroparesis. It suggests the medication worsens symptoms or triggers the condition.

Wegovy Research and Medical Studies

Recent studies focus on Wegovy’s role in users developing gastroparesis. GLP-1 agonists, including semaglutide, play a crucial role in this research. They have been found to slow stomach emptying. This slowing is a leading symptom of gastroparesis.

There are potentially significant legal implications associated with these studies. They support the lawsuit claims on side effects.

The study results are mixed when it comes to semaglutide use and thyroid cancer. There is some evidence that it causes cancer in rodents, but human evidence is not conclusive. 

A 2022 French study observed an increase in thyroid cancer among semaglutide users. 

However, in 2023, a review found no strong association of semaglutide with cancer. The European Medicines Agency also didn’t find any direct cancer link.

In another study, approximately one-third reported significant side effects. Seventeen percent discontinued the use of Wegovy due to GI problems. Only 8% of the placebo group did the same.

Who Can File a Wegovy Semaglutide Lawsuit?

Some Wegovy patients diagnosed with gastroparesis may wish to explore their legal options. This also applies to patients who, after starting Wegovy, experienced severe side effects.

Please note that these cases require a clear connection between the two. Gastroparesis symptoms must be clearly related to the use of Wegovy.

If you believe your health issues are related to Wegovy, an attorney can help assess your case and determine whether legal action is appropriate. If you qualify, they may help collect medical records and documentation to support your claim.

What to Expect When Filing a Wegovy Lawsuit

Here is the process:

  1. First Consultation: You start by meeting with our partners for a free and confidential case review. They consider how Wegovy affects your health.
  2. Case Preparation: Our partners assist you in gathering all necessary documents. This includes medical records and evidence of side effects. Their team guides you through documenting your experiences to strengthen your claim.
  3. Navigating Legal Proceedings: Our partners manage the initial filings and oversee the legal processes. You’ll be kept informed throughout the process.

Continued Support: Our partners are by your side throughout the process. Continuous support and updates will be provided.

Consult a Wegovy Lawyer Today

Note: Fill out the form or call to see if legal options may be available. Inquiries will be shared with a partner law firm under a marketing arrangement to assist with next steps.

Are you experiencing serious side effects after using Wegovy? You may want to consult with a lawyer to discuss your legal rights and options. At Winder Law Firm, we understand that injury cases are very involved. Our partners are here to help walk you through the process.
You can request a free consultation today. If you’ve been affected, you may be eligible to explore a legal claim. Each case is unique, and compensation is not guaranteed. Fill out the contact form to request a free case review.

Resources for Gastroparesis Patients

If you or someone you know is managing gastroparesis, several resources are available. They can provide support, medical info, and advocacy.

Most Asked Questions

CONTACT US IF YOU STILL HAVE QUESTIONS

Fact Checked

Winder Law Firm strives to provide accurate and timely information, but the content on this page is for informational purposes only and should not be taken as legal advice. If you need legal guidance or are considering legal action, consult an attorney. This website strives to follow applicable state bar and ABA ethical marketing rules. We are not responsible for third-party content, including linked law firms or services, and do not endorse or recommend them. We bear no liability for security risks or issues from external links.

View our editorial guidelines for more details.

Legally Approved

The content on this page has been reviewed for legal accuracy by Attorney Aaron A. Winder. This content is for informational purposes only and not legal advice. It is not a substitute for professional legal counsel. Winder Law Firm does not guarantee this website content’s accuracy, completeness, or relevance. This website may contain inaccuracies, typographical errors, or outdated information and does not necessarily reflect the firm’s or its employees’ opinions. Consult an attorney for legal guidance.

Legally Reviewed

The content on this page has been reviewed for legal accuracy by Attorney Aaron A. Winder. This content is for informational purposes only and not legal advice. It is not a substitute for professional legal counsel. Winder Law Firm does not guarantee this website content’s accuracy, completeness, or relevance. This website may contain inaccuracies, typographical errors, or outdated information and does not necessarily reflect the firm’s or its employees’ opinions. Consult an attorney for legal guidance.

Award Methodology

The CALI Excellence for the Future Award® is given to the highest-scoring student in a law school course, as determined by the instructor or registrar. This award recognizes academic excellence in legal education and is granted by the Center for Computer-Assisted Legal Instruction (CALI), a nonprofit consortium of law schools and organizations.

Attorney Aaron A. Winder, owner of Winder Law Firm, received this award in Advanced Criminal Procedure while studying at Gonzaga University School of Law.

More information about the CALI Excellence for the Future Award® can be found at CALI’s website.

This recognition has not been reviewed or approved by any state supreme court or bar association.

Disclaimer

This page offers general information, not legal advice, and does not create an attorney‑client relationship. Allegations mentioned are unproven in court. Information is based on public sources. Inquiries are shared with a partner firm under a marketing arrangement.